SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as the community discusses recent developments including Gravity SUV deliveries in Canada and a partnership with Riyadh Season. Despite positive news, concerns persist around production targets, potential dilution, and the company's overall financial health, fueling debate among investors. Some are optimistic about Lucid's technology and long-term potential, while others express skepticism about its ability to compete effectively in the EV market.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as chatter swirls around a recent SEC filing showing the CEO sold a significant number of shares, sparking debate about potential conflicts of interest and motives behind the sale. Some traders are taking bearish stances and pointing to potentially overvalued conditions, while bulls are hoping the stock can shake off the negative sentiment with its expansion into the menopause market and potential short squeeze.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending due to positive sentiment around potential upgrades and community excitement about its gains, with some eyeing a move to double digits. Bullish traders are celebrating recent wins and expressing confidence in the stock's undervaluation, citing Wedbush's price target. However, some caution exists regarding potential pullbacks, with a few traders closing positions for profit.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine ($APPS) is trending as investors discuss its potential in the evolving app store landscape following recent rulings and potential AI partnerships; the community is actively debating whether the stock's current momentum is sustainable and if it can maintain its upward trajectory, with some closely watching for a breakout while short positions may get squeezed. Broader discussions cover the company's restructuring, potential acquisitions, and impact of broader market trends.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders weigh positive catalysts like potential US-China trade talks against concerns about high valuations and regional banking risks. Community discussions focus on whether the current market action is a bull trap or the start of a sustained rally, with many observing unusual price swings and questioning the influence of algorithmic trading. Some traders are pointing to Trump's comments on China and potential interest rate cuts as bullish signals, while others remain cautious, citing overbought conditions and a potential for a pullback.

Firecoin is a digital asset inspired by the concept of the eternal flame, representing energy, resilience, and guidance. It is designed to act as a decentralized token that embodies light and strength, giving holders a sense of empowerment in the digital economy. The project’s purpose is to create a community-driven ecosystem where Firecoin symbolizes progress, illumination, and the ability to move forward regardless of challenges. By leveraging blockchain technology, Firecoin aims to provide transparency, security, and accessibility to its users while maintaining its thematic connection to the symbolic power of fire.

firecoin

$FIRECOIN is experiencing a surge in interest, with community members actively discussing its availability on Phantom Wallet and potential for high gains. The conversation is centered around whether it's a legitimate opportunity or a 'scam,' with some users reporting significant gains while others express skepticism. Many are using Phantom Wallet to monitor activity and track the token's performance relative to other cryptocurrencies like $BTC and $SOL.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as traders digest potential shifts in US-China trade relations following comments from former President Trump, contributing to market volatility. Community discussions revolve around identifying key support and resistance levels, with some expressing skepticism about the market's overall strength. Traders are also monitoring the impact of potential bank failures and geopolitical events on the ETF's performance.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on September 3, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave is trending as traders discuss a potential breakout above the $12.50 resistance, with some pointing to the stock's low float and potential in the AI and defense sectors. Community members are also eyeing call options, anticipating a significant move, while others highlight the company's AI, drone, and sensing technologies, drawing comparisons to $PLTR. Chatter also mentions a recent advisory board formation and successful UAE live-fire trial as potential catalysts.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending amid rumors of a potential acquisition by Eli Lilly ($LLY), fueled by mentions in the Betaville blog and community speculation around trial updates and a possible settlement.  The community is buzzing about the acquisition potential and upcoming trial results, with many suggesting a settlement could be imminent. Bullish sentiment is further supported by a price target increase from B. Riley Securities.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

ATAI Life Sciences N.V.

ATAI is trending after receiving FDA Breakthrough Therapy Designation for its depression treatment, BPL-003, driving excitement among investors. Community members are discussing Jefferies' raised price target to $10 and the potential for Phase 3 trials, while also weighing the impact of a recent public offering.  The stock is viewed by some as a long-term play in the burgeoning psychedelic medicine sector, drawing comparisons to $TSLA and $NVDA.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharma stocks crack, Nifty Pharma Index slips over 2% as Trump unveils 100% tariff: 3 key factors investors must watch

… and patented drugs entering … pharma space include the likes of Natco Pharma , Laurus Labs, Alembic Pharma , Sun Pharma … , Gland Pharma , Ajanta Pharma , and Glenmark Pharmaceuticals … of Indian pharmaceutical exports. …

India's $30B Pharma Export Market Faces Heat from Trump's Tariff

… on branded and patented pharmaceuticals , as announced by President … on branded and patented pharmaceutical products beginning October 1, … Aurobindo Pharma , Zydus Lifesciences, Sun Pharma and Gland Pharma derive between … to make high-end drugs such as cancer and …

Healthcare stocks in India fell on Friday as investors weighed the impact of U.S. President Donald Trump’s move to impose a 100% tariff on branded and patented drugs starting Oct. 1.&nbsp;The measure, announced in late-night Truth Social posts, exempts only those manufacturers with U.S. plants that are already under construction or have broken ground.The Nifty Healthcare index fell 1.2% on Thursday, with 18 of its 20 components trading lower.&nbsp;IPCA Laboratories remained unchanged, while Torrent Pharma rose 0.01%.Analyst ViewSEBI-registered analyst&nbsp;<a href="https://stocktwits.com/ra_vishaltrehan">Vishal Trehan</a> said Gland Pharma is the most exposed, given its lack of a U.S. manufacturing footprint and reliance on branded or patented formulations.&nbsp;<stembedurl>https://stocktwits.com/ra_vishaltrehan/message/630078378</stembedurl>He noted that Syngene International, Piramal Pharma, and Zydus Lifesciences stand to benefit from their contract manufacturing models and biologics portfolios, which are less tariff-sensitive.Trehan also pointed out that companies with a large branded generics or biosimilars presence, such as Dr. Reddy’s Laboratories and Biocon, will need to accelerate U.S. production to avoid margin erosion.Trump’s Pharma TariffsThe announcement builds on Trump’s escalating trade measures aimed at repatriating drug manufacturing. Last month, he outlined a phased plan, beginning with a “small tariff” on imported drugs, before lifting duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had earlier been excluded from his reciprocal tariff program, but the new rules extend to prescription medicines, biologics, specialty drugs, and over-the-counter products, with generic drugs remaining exempt.What Is The Retail Mood?On Stocktwits, retail sentiment for Piramal Pharma, Zydus Lifesciences, and Dr. Reddy’s Laboratories was ‘bearish’ amid ‘normal’ message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/GLAND.NSE">Gland Pharma</a> has risen 6.5%, while&nbsp;<a href="https://stocktwits.com/symbol/SYNGENE.NSE">Syngene International</a> is down 29.1%,&nbsp;<a href="https://stocktwits.com/symbol/PPLPHARMA.NSE">Piramal Pharma</a> has slipped 25.9%,&nbsp;<a href="https://stocktwits.com/symbol/ZYDUSLIFE.NSE">Zydus Lifesciences</a> is up 1.8%,&nbsp;<a href="https://stocktwits.com/symbol/DRREDDY.NSE">Dr. Reddy’s Laboratories</a> is down 7.2%, and&nbsp;<a href="https://stocktwits.com/symbol/BIOCON.NSE">Biocon</a> has fallen 6.3%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

India’s Healthcare Index Sinks After Trump’s Pharma Tariff Blow — SEBI Analyst Sees Risks For Gland, Biocon, Dr. Reddy’s

The analyst noted that Syngene, Piramal Pharma, and Zydus Lifesciences may be better positioned, as their contract manufacturing models and biologics portfolios are less susceptible to the tariff impact.

Equity

Business News | Trump's 100% Tariff on Patented Drugs Puts Spotlight on India's USD 30 Billion Pharma Export Market

… on branded and patented pharmaceutical products beginning October 1 … Aurobindo Pharma , Zydus Lifesciences, Sun Pharma and Gland Pharma derive … to make high-end drugs such as cancer … Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. …

US President Donald Trump Announces Tariffs Up To 100% On Pharma, Starting October 1, 2025

India supplies over 45 per cent of generic and 15 per cent of biosimilar drugs used in the US. Firms like Dr Reddy's, Aurobindo Pharma, Zydus Lifesciences, Sun Pharma, and Gland Pharma reportedly earn anywhere from 30-50 per cent of their total revenues from the American market.

Why has US goverment given exemption to Indian pharmaceutical sector

The US granted a crucial exemption to India’s pharmaceutical industry from recent tariffs, recognizing the critical role of Indian generics in maintaining affordable healthcare. While initially a 50% tariff was imposed, the exemption protects the sector, preventing disruption to US drug access. Major Indian pharmaceutical players like Zydus Lifesciences, Dr. Reddy’s, Gland Pharma, and Biocon, heavily reliant on the US market, would be significantly impacted.

Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. It offers injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, and ophthalmic solutions. The company was founded by P. V. N. Raju in 1978 and is headquartered in Sangareddy, India.

GLAND.NSE
Gland Pharma Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GLAND.NSE News

GLAND.NSEGland Pharma Ltd.